source
- nPhase unveils AI-driven clinical data platform to accelerate trial design and submissionnPhase, a clinical research organization, announced the launch of an end-to-end platform called nPhase.ai that uses artificial intelligence to manage clinical trial data. The platform includes a S…
- BMS reports positive mid-stage results for arlo-cel in heavily pre-treated myeloma patientsBMS said its CAR T therapy arlo-cel, formally arlocabtagene autoleucel, achieved positive results in a registrational mid-stage study for relapsed and refractory multiple myeloma. The open-label,…